(Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating street estimates.
Net profit came in at 9.83 billion rupees ($140.6 million) for the three months ended June 30, compared with a loss of 4.25 billion rupees a year earlier, the company said https://www.bseindia.com/xml-data/corpfiling/AttachLive/7fb22856-27f5-4c99-a74d-d3ae63002daa.pdf.
In the year-ago quarter, Sun Pharma incurred costs of 9.51 billion rupees related to settlements in a U.S. antitrust case over sleep disorder drug Modafinil.
Analysts on average expected a net profit of 8.97 billion rupees.
Total revenue from operations rose about 16 percent to 72.24 billion rupees.
($1 = 69.9300 Indian rupees)
(Reporting By Arnab Paul in Bengaluru; Editing by Gopakumar Warrier)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)